What Happens to Compounded GLP-1s After June 29 — and What to Take Instead

The short version: If you've been getting compounded semaglutide or tirzepatide from an outsourcing pharmacy (a "503B facility"), your supply is ending. Today is the last business day before the FDA's compliance deadline — and tomorrow, June 29, those 503B compounders must stop making these drugs. You're not out of options, and for many people this change may actually open a better, cheaper path forward. Here's exactly what's happening and what to do.

What Is a 503B Compounder and Why It Matters

During the GLP-1 drug shortage of 2023–2025, the FDA allowed two types of pharmacies to legally compound (custom-make) versions of semaglutide and tirzepatide:

503A pharmacies — traditional compounding pharmacies that make drugs for individual prescriptions
503B outsourcing facilities — larger operations that can produce drugs in bulk without patient-specific prescriptions

503B facilities are the ones supplying the high-volume telehealth platforms — the services where you fill out a form online, get approved by a provider, and receive pre-filled syringes in the mail. They operate at scale, which kept prices low and supply steady when Ozempic and Wegovy were backordered.

The FDA declared the semaglutide shortage resolved in early 2025 and the tirzepatide shortage resolved shortly after. When a shortage ends, the legal basis for 503B compounding disappears. The FDA gave outsourcing facilities an extended compliance window — that window closes tomorrow, June 29, 2026.

After that date, 503B facilities cannot legally manufacture new batches of compounded semaglutide or tirzepatide. Existing inventory may ship through, but new production stops.

What the FDA Comment Period Actually Means

You may have seen notices that a "comment period" closes today. Here's what that refers to without the bureaucratic fog:

The FDA proposed guidance documents that clarify exactly which compounded versions of these drugs are permissible going forward — particularly around "essentially a copy" restrictions and personalization exceptions. The comment window for that proposed guidance closes June 29.

This matters because the final rules will determine whether 503A compounding pharmacies (the smaller, patient-specific ones) can continue making these drugs in limited circumstances — for example, if a patient has a documented allergy to a brand-name excipient, or needs a dose that isn't commercially available.

What it does NOT mean: The comment period closing doesn't delay the 503B deadline. Those large-scale operations are done regardless of how comments shake out. The comment period affects the longer-term fate of small-volume, individualized compounding only.

What Happens If You're Currently on Compounded GLP-1s

Scenario 1: You get your supply from a 503B-backed telehealth service

Platforms like Hims, Ro, and similar services sourced from 503B facilities. Many have already been winding down their compounded GLP-1 programs — some quietly, some with formal notices to patients.

If you haven't received a transition notice yet, check your account. You likely have a few weeks of supply left if a shipment already went out, but do not expect refills at the same source.

Scenario 2: You have a prescription at a 503A compounding pharmacy

Traditional compounding pharmacies fill individual prescriptions. Their legal situation after June 29 is more nuanced — they can still compound in limited circumstances under a valid prescription, particularly if there's a documented clinical need that brand-name products don't meet.

Talk to your prescribing provider and pharmacy specifically. Don't assume either "it's still fine" or "I have to stop immediately."

Scenario 3: You've been buying compounded GLP-1s without a prescription

Stop. If you've been purchasing compounded semaglutide peptides from research chemical suppliers or unvetted online sources, the regulatory crackdown here is the least of your problems. The purity, dosing, and sterility of these products is unverified. This is a real safety concern, not a compliance technicality.

The Medicare July 1 Inflection Point — This Is Actually Good News

Here's the part most coverage is missing: the same week compounded GLP-1s phase out, Medicare coverage for GLP-1 medications for obesity treatment expands.

Starting July 1, 2026, Medicare Part D plans are required to cover FDA-approved GLP-1 drugs prescribed for weight management — not just for Type 2 diabetes. This is a significant change. Previously, Medicare covered Ozempic and Rybelsus for diabetes but explicitly excluded coverage of Wegovy or Zepbound when prescribed for obesity alone.

For the millions of Americans over 65 on Medicare who have been paying out-of-pocket for compounded versions specifically because the brand-name drugs weren't covered, this is a genuine path to affordability.

What you need to do: Contact your Part D plan administrator and ask about your formulary coverage for Wegovy (semaglutide 2.4mg) or Zepbound (tirzepatide). Coverage and cost-sharing vary by plan, but the legal requirement to offer coverage is now in place. If you're not on Medicare, check whether your commercial insurer has updated their prior authorization criteria — many have loosened requirements as the drugs have become more mainstream.

Your Actual Options After June 29

Option 1: Transition to Brand-Name FDA-Approved GLP-1s

This is the most straightforward path for most people. The FDA-approved options are:

For weight loss (obesity-indicated):

Wegovy (semaglutide 2.4mg weekly injection) — same molecule as Ozempic, higher dose, approved for chronic weight management
Zepbound (tirzepatide weekly injection) — dual GIP/GLP-1 agonist; clinical trials showed greater average weight loss than semaglutide

For Type 2 diabetes (with secondary weight benefit):

Ozempic (semaglutide 0.5mg, 1mg, 2mg weekly injection)
Mounjaro (tirzepatide weekly injection)
Rybelsus (oral semaglutide, daily pill — less effective for weight than injectable but no needles)

The argument for brand-name is simple: verified dosing, verified purity, manufacturer support programs, and now better insurance coverage than 12 months ago. Both Novo Nordisk and Eli Lilly have patient savings programs — ask your prescriber or pharmacy about manufacturer savings cards if you're paying out of pocket.

Option 2: Oral GLP-1 Medications (Lower Barrier, Emerging Data)

If injections are a dealbreaker, oral options have improved. Rybelsus (oral semaglutide) is FDA-approved for Type 2 diabetes and shows meaningful weight loss, though less than the injectable forms. For people who want the mechanism without the weekly shot, it's a legitimate conversation to have with your provider.

Oral tirzepatide formulations are in late-stage trials. Keep an eye on this space — approval could come within 12–18 months.

Option 3: Non-GLP-1 Prescription Weight Loss Medications

Not everyone is a GLP-1 candidate. If cost, access, or side effects have been barriers, other FDA-approved options exist:

Contrave (naltrexone/bupropion) — works on the dopamine/opioid reward pathway, not GLP-1 mechanism; often better tolerated digestively
Qsymia (phentermine/topiramate extended-release) — older drug, strong efficacy data, significantly cheaper
Orlistat — blocks fat absorption, available OTC as Alli; modest efficacy, significant GI side effects, not a fit for everyone

These aren't GLP-1s and won't produce the same outcomes for most people. But they're real, studied options with established safety records — not supplements with vague claims.

Option 4: Structured Metabolic Programs

For people who were using compounded GLP-1s at low doses as a "boost" alongside diet changes, a structured metabolic program may deliver comparable results without medication:

Low-carbohydrate or ketogenic dietary protocols with metabolic monitoring
Time-restricted eating (intermittent fasting) with protein targets
Medically supervised very low calorie diet (VLCD) programs

These require more consistency and behavioral commitment than weekly injections, but they're not placebo — the research on low-carb metabolic intervention is substantial. If you've been on GLP-1s for less than six months and haven't made parallel diet changes, this transition period is a forcing function to build the habits that make any weight intervention last.

We've found Levels continuous glucose monitoring useful for this — real-time feedback on how food affects your blood sugar makes dietary changes click in a way abstract advice doesn't.

Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, we may earn a small commission at no extra cost to you. We only recommend products we genuinely believe in. This helps support our work and allows us to continue providing free content.

What NOT to Do This Week

A few things to avoid in the scramble:

Don't panic-buy from unvetted sources. Compounded GLP-1 peptides sold through research chemical websites or unregulated overseas pharmacies are not a solution. The enforcement environment around these products is tightening alongside the 503B crackdown, and the product quality isn't guaranteed.

Don't abruptly stop if you've been on these medications for more than three months. GLP-1 medications work partly by suppressing appetite signals. Coming off them without a plan — dietary, behavioral, or otherwise — frequently results in weight regain. Talk to your prescriber about a taper plan or transition strategy before your last dose.

Don't assume your telehealth provider will solve this for you automatically. Some will; many won't. Be proactive. Log into your portal, check your messages, and contact them directly if you're uncertain about your supply.

How to Talk to Your Doctor About This

If you've been getting compounded GLP-1s through a telehealth platform without involving your primary care provider, now is a good time to bring them in. Here's what to ask:

"Am I a candidate for a brand-name GLP-1 prescription, and can you help me pursue prior authorization through my insurer?"
"Given the July 1 Medicare changes, what does my Part D plan cover for weight management?"
"If GLP-1s aren't covered or affordable for me, what alternatives do you recommend given my metabolic history?"

Your primary care provider can also order labs — A1C, fasting insulin, lipid panel — that help contextualize whether medication intervention is warranted and which category of drug fits your clinical picture.

The Bottom Line

June 29 is a real deadline with real consequences for people relying on 503B-sourced compounded GLP-1s. The supply chain disruption is genuine. But the timing is not purely bad news.

The Medicare expansion on July 1 creates legitimate access to brand-name medications for millions of Americans who were previously priced out. The compounding era drove adoption of GLP-1s broadly — that awareness and the clinical infrastructure built around it doesn't disappear because the compounded supply does.

If you're currently on a compounded GLP-1, you have a narrow but real window to make a clean transition. Act this week, not next month.

Last updated: 2026-06-28

Get the weekly update. Our newsletter covers FDA regulatory changes, insurance coverage shifts, and evidence-based weight loss strategies — no hype, no sales pitches. Enter your email below and we'll send you the next issue.